<SEC-DOCUMENT>0001558370-22-014659.txt : 20220927
<SEC-HEADER>0001558370-22-014659.hdr.sgml : 20220927
<ACCEPTANCE-DATETIME>20220927172027
ACCESSION NUMBER:		0001558370-22-014659
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220927
DATE AS OF CHANGE:		20220927

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOPHARMA, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38247
		FILM NUMBER:		221272149

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tmb-20220927xdefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 9/27/2022 03:26:05 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:14pt;font-weight:bold;">SCHEDULE 14A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(RULE 14a-101)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INFORMATION REQUIRED IN PROXY STATEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SCHEDULE 14A INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Proxy Statement Pursuant to Section 14(A) of the</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 6pt 0pt;">Filed by the Registrant&#8195;<font style="font-family:'MS PGothic';">&#9746;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 6pt 0pt;">Filed by a Party other than the Registrant&#8195;<font style="font-family:'MS PGothic';">&#9744;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 6pt 0pt;">Check the appropriate box:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'MS PGothic';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9744;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Preliminary Proxy Statement</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'MS PGothic';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9744;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></td></tr></table><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'MS PGothic';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9744;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Definitive Proxy Statement</font></td></tr></table><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'MS PGothic';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9746;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Definitive Additional Materials</font></td></tr></table><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'MS PGothic';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9744;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Soliciting Material Pursuant to &#167; 240.14a-12</font></td></tr></table><div style="margin-top:12pt;"></div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">Aytu BioPharma, Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Name of Registrant as Specified In Its Charter)</p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Name of Person(s) Filing Proxy Statement if other Than the Registrant)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:12pt 0pt 6pt 0pt;">Payment of Filing Fee (Check the appropriate box):</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'MS PGothic';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9746;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">No fee required.</font></td></tr></table><div style="margin-top:6pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'MS PGothic';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9744;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Fee paid previously with preliminary materials.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'MS PGothic';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9744;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><img src="tmb-20220927xdefa14a001.jpg" alt="Aytu BioPharma Announces Launch of Public Offering" style="display:inline-block;height:100.04pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:145.06pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#ff0000;font-weight:bold;">**** URGENT REMINDER ****</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="color:#ff0000;font-weight:bold;">YOUR IMMEDIATE ATTENTION IS REQUESTED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dear Aytu BioPharma, Inc. Stockholder:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Time is growing short before the Aytu BioPharma, Inc. Special Meeting which is scheduled to be held on October 5, 2022. You are receiving this reminder letter because your votes were not yet processed at the time that this letter was mailed. If you have already voted, we would like to thank you for your vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="color:#ff0000;font-style:italic;font-weight:bold;">****PLEASE VOTE TODAY****</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 18pt 0pt;">Your Board recommends that you vote <b style="font-weight:bold;">FOR </b>proposals 1, and 2. &#160;It is very important that the reverse stock split be approved, as it will help allow the company to maintain its listing on NASDAQ and every shareholder&#8217;s vote is extremely important.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#ff0000;font-weight:bold;text-decoration-color:#ff0000;text-decoration-line:underline;text-decoration-style:solid;">WE URGE YOU TO EXERCISE YOUR RIGHT TO VOTE TODAY.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 24pt 0pt;"><font style="font-style:italic;font-weight:bold;">If you have questions or need help voting your shares, please call our proxy solicitation firm, Morrow Sodali LLC at 1-800-607-0088.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 18pt 0pt;">Thank you for your investment in Aytu BioPharma, Inc. and for taking the time to vote your shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 30pt 0pt;">Sincerely,</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">Joshua Disbrow</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Chairman and Chief Executive Officer</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tmb-20220927xdefa14a001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20220927xdefa14a001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #) 2,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=7R]_P %$/VO_P#A4'A:7P-X7NA_PEVK0E9YXSS8V[ @GV<C@>G6OC[]C?\
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M(S[!G>IR<@\?A7-GX8:U=>'[/3;S07NKPZVLNKW,TZR)J,9^],,]L?PXXIV
M]P\2^+=$\(Z1_:>K7L-I9$J%E8YW$] ,=<^U/USQ?I'AG0&UK4KQ+33517,S
M@]#TXZUY'X[^!4Y\,:JFGSW&N21;1HVFW3#R[!<\[">I]">E6]8\"^*O&GB#
M24D^SZ9H^@P)Y45_&)UO;@H SE58?*O;/>D!Z_IFJ6NLZ?;WUE,MQ:SH)(Y$
M.0RGO5NO,_A/X1\1> [W5='OYH;_ $1V^UV=S$/+$3LQW0A,G"C[V<]Z],H
M**** "BBB@ I,#TI:* $P/2C%+10 F!Z48I:* $Q1@>@I:* "BBB@ HHHH *
M*** "BBB@ HHHH **** $HP/2EHH 3%&*6B@!,"EHHH 3 STH(SUI:* $P/2
MC S2T4 )BC%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
